NeuroHealing Pharmaceuticals Appoints Mark Leuchtenberger to Board of Directors

Newton, Massachusetts – September 3, 2013 – NeuroHealing Pharmaceuticals, a private clinical stage company developing drug treatments for individuals with neuro-rehabilitation needs, today announced the appointment of Mark Leuchtenberger to the company’s Board of Directors. Mark Leuchtenberger was most recently the President & CEO of Rib-X Pharmaceuticals until its acquisition by Vatera Healthcare in January…

The Michael J. Fox Foundation Grants Second Award to NeuroHealing for Clinical Trial of NH004 for Sialorrhea Control in Parkinson’s Disease

Newton, Massachusetts – August 26, 2011. NeuroHealing Pharmaceuticals, a private, clinical stage company developing drug treatments for individuals with neuro-rehabilitation needs, announced today that The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded the company a grant to advance the clinical development of NH004, a novel treatment for sialorrhea (uncontrolled drooling). This grant…

NeuroHealing Announces Orphan Drug Designation in Europe for NH001 for the Treatment of Patients Following a Moderate or Severe Traumatic Brain Injury

Provides a 10-Year Regulatory Exclusivity for the European Community Newton, Massachusetts – May 23, 2011. NeuroHealing Pharmaceuticals today announced that the European Commission has granted Orphan Drug Designation EU/3/11/862 for NH001 for the treatment of patients following a moderate or severe traumatic brain injury (TBI). The designation follows a positive opinion from the Committee for…

NeuroHealing Announces Strategic Master Services and Investment Agreement with Cato BioVentures

Newton, Massachusetts – May 16, 2011. NeuroHealing Pharmaceuticals today announced that it has entered into a strategic master services and investment agreement with Cato BioVentures. This agreement includes a collaboration with Cato Research Ltd. (“Cato”), its global contract research organization, to assist in the clinical development of NeuroHealing’s lead drug NH001. The investment and collaboration…

NeuroHealing Announces Issuance of U.S. Patent for Brain Injury Treatment

Newton, Massachusetts – May 9, 2011. NeuroHealing Pharmaceuticals announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application 11/240,281 entitled “High Potency Dopaminergic Treatment of Neurological Impairment Associated with Brain Injury.” U.S. Patent 7,943,632 will issue May 17, 2011. The patent claims cover methods and…